Nové pracovní příležitosti
Prozkoumejte pracovní příležitosti ve společnosti Novartis v seznamu níže.
Showing 711 results
- Sort by Sort ascending
- Pracovní pozice Seřadit vzestupně
- Byznys
- Místo
- Pobočka
- Datum zveřejnění
| Pracovní pozice Seřadit vzestupně | Byznys | Místo | Pobočka | Datum zveřejnění |
|---|---|---|---|---|
| Senior QA Expert ESO Temporary (Fixed Term), Full time | Quality | Poland +Alternative Locations | Warsaw | pro 02, 2025 |
| Radioligand Therapies (RLT) Associate Director, Priority Accounts - Chicago Regular, Full time | General Management | USA +Alternative Locations | Field Non-Sales (USA) | pro 02, 2025 |
| Radioligand Therapies (RLT) Associate Director, Priority Accounts – Salt Lake City Regular, Full time | General Management | USA +Alternative Locations | Field Non-Sales (USA) | pro 02, 2025 |
| Radioligand Therapies (RLT) Associate Director, Priority Accounts - Virginia - Carolinas Regular, Full time | General Management | USA +Alternative Locations | Field Non-Sales (USA) | pro 02, 2025 |
| Radioligand Therapies (RLT) Associate Director, Priority Accounts – Phoenix Regular, Full time | General Management | USA +Alternative Locations | Field Non-Sales (USA) | pro 02, 2025 |
| Radioligand Therapies (RLT) Associate Director, Priority Accounts - Pennsylvania Regular, Full time | General Management | USA +Alternative Locations | Field Non-Sales (USA) | pro 02, 2025 |
| Radioligand Therapies (RLT) Associate Director, Priority Accounts - Boston, MA Regular, Full time | General Management | USA +Alternative Locations | Field Non-Sales (USA) | pro 02, 2025 |
| Director, Business Excellence Lead, ASCVD Regular, Full time | General Management | USA | East Hanover | pro 02, 2025 |
| Radioligand Therapies (RLT) Associate Director, Priority Accounts - Mid - Atlantic Regular, Full time | General Management | USA +Alternative Locations | Field Non-Sales (USA) | pro 02, 2025 |
| Associate Director Evidence Partnerships & Solutions Regular, Full time | Development | India | Hyderabad (Office) | pro 02, 2025 |